NCT06304103View on ClinicalTrials.gov

A Study of Efficacy and Safety of AND017 in Patients with Myelodysplastic Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

AND017

Administer AND017 once per day (QD)

Sponsors
All Listed Sponsors
lead

Kind Pharmaceuticals LLC

INDUSTRY